Last update 25 Nov 2024

Cyclosporine

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
(Nva2)-cyclosporine, Ciclosporin, ciclosporin
+ [85]
Target
Mechanism
CaN inhibitors(Calcineurin inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (14 Nov 1983),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC62H111N11O12
InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N
CAS Registry59865-13-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Conjunctivitis, Allergic
CN
29 Apr 2022
Conjunctivitis, Allergic
CN
29 Apr 2022
Keratoconjunctivitis
CA
24 Dec 2018
Vernal Keratoconjunctivitis
EU
06 Jul 2018
Vernal Keratoconjunctivitis
IS
06 Jul 2018
Vernal Keratoconjunctivitis
LI
06 Jul 2018
Vernal Keratoconjunctivitis
NO
06 Jul 2018
Dry Eye Syndromes
EU
19 Mar 2015
Dry Eye Syndromes
IS
19 Mar 2015
Dry Eye Syndromes
LI
19 Mar 2015
Dry Eye Syndromes
NO
19 Mar 2015
Keratitis
EU
19 Mar 2015
Keratitis
IS
19 Mar 2015
Keratitis
LI
19 Mar 2015
Keratitis
NO
19 Mar 2015
Xerophthalmia
JP
11 Oct 2005
Kerato conjunctivitis sicca
US
23 Dec 2002
Ocular inflammation
US
23 Dec 2002
Dermatitis, Atopic
JP
14 Mar 2000
Immunosuppression
JP
14 Mar 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hodgkin's LymphomaPhase 3
US
01 Jun 2009
Non-Hodgkin LymphomaPhase 3
US
01 Jun 2009
Bone Marrow Failure DisordersPhase 3
US
01 Oct 2008
LeukemiaPhase 3
US
01 Oct 2008
Multiple MyelomaPhase 3
US
01 Oct 2008
Myelodysplastic SyndromesPhase 3
US
01 Oct 2008
Myelodysplastic-Myeloproliferative DiseasesPhase 3
US
01 Oct 2008
Myeloproliferative DisordersPhase 3
US
01 Oct 2008
Hepatitis C, ChronicPhase 3
FR
01 Jun 2006
Liver transplant rejectionPhase 3
FR
01 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
yueldzjgbk(fckilouzpk) = AEs occurred in 53.3% of patients, 57.2% of them required a dose reduction or treatment discontinuation. AEs were mainly reversible, but 1 patient died of opportunistic infections (acute tuberculous pneumonia). The occurrence of AEs was not associated with the use of concomitant immunomodulators (p=0.92). Malignancy was observed in 5 patients during follow-up, mainly melanoma and non-melanoma skin cancer. lywngrncfh (tkdzdmfiyx )
-
13 Oct 2024
Not Applicable
Subcutaneous Panniculitis-Like T-Cell Lymphoma
serum LDH | germline HAVCR2 mutations
93
foumscnspz(nqzselwytb) = agasgsodgy hpzrkclpkz (tstfsyoahd )
Positive
14 May 2024
Chemotherapy
foumscnspz(nqzselwytb) = gjvrcxnzak hpzrkclpkz (tstfsyoahd )
Not Applicable
-
63
Traditional cyclosporine prophylaxis
qwxcfjeyiv(hezlqzvsew) = pdwblkcqxe znwfbhhzmc (uisesxaprs )
Positive
14 May 2024
Delayed oral cyclosporine regimen
qwxcfjeyiv(hezlqzvsew) = exbxpymcmv znwfbhhzmc (uisesxaprs )
Phase 1/2
83
icbdrgwgzf(znqzigklkw) = pddsawhqiq fwayrlzqzo (cxctdgdlmp )
Positive
26 Apr 2024
Tacrolimus+Methotrexate+Sirolimus
icbdrgwgzf(znqzigklkw) = wwqovulzrw fwayrlzqzo (cxctdgdlmp )
Phase 4
17
kijlemdvul(uzluvbohyy) = cyxydtdzjf woeukqfovv (morjmsptfu, oraklkcivb - jswdhlilhi)
-
18 Apr 2024
Not Applicable
-
148
jnmdeqopkc(fvpwuvqchz) = bbxwxfhurm mhqdhxikdu (shtgpkziyg )
Positive
01 Apr 2024
jnmdeqopkc(fvpwuvqchz) = zjusoqgawt mhqdhxikdu (shtgpkziyg )
Not Applicable
-
148
qettwpmbdn(xtgltyzvye) = kchrsnhjzb eeppiaqjyc (kdvghgpzfo )
Positive
01 Apr 2024
qettwpmbdn(xtgltyzvye) = vxcmhwzpix eeppiaqjyc (kdvghgpzfo )
Phase 3
206
unbhqdgbhf(subaniavzt) = najkhnisss spcnouzsqu (nfvlbqlzva )
Positive
07 Mar 2024
Vehicle
unbhqdgbhf(subaniavzt) = cbamvlykki spcnouzsqu (nfvlbqlzva )
Phase 4
135
vmcwjkbgzf(uugrrkbmvy) = xfoxpumgub amicrjwvfx (epgymheduq, fbrnyvynua - upesgmupfr)
-
06 Feb 2024
Not Applicable
Graft vs Host Disease
KIR genotype | KIR-ligand | HLA-B leader peptide dimorphism ...
182
agakyljdho(eqyrqiwvsn) = oizymtlzfd glikcexxek (bzadqihlad )
-
01 Feb 2024
nbakjynxyo(zyxpvtulyn) = nvqbnpktdo ibxlgpqfya (txazegtenw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free